311 related articles for article (PubMed ID: 28127516)
1. Serum uric acid levels in Parkinson's disease and related disorders.
Sakuta H; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Watanabe Y; Hirata K
Brain Behav; 2017 Jan; 7(1):e00598. PubMed ID: 28127516
[TBL] [Abstract][Full Text] [Related]
2. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
[TBL] [Abstract][Full Text] [Related]
3. Low serum uric acid levels in progressive supranuclear palsy.
Oropesa-Ruiz JM; Huertas-Fernández I; Jesús S; Cáceres-Redondo MT; Vargas-Gonzalez L; Carrillo F; Carballo M; Gómez-Garre P; Mir P
Mov Disord; 2016 Mar; 31(3):402-5. PubMed ID: 26686202
[TBL] [Abstract][Full Text] [Related]
4. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
Yoshita M; Hayashi M; Hirai S
Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
[TBL] [Abstract][Full Text] [Related]
5. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy.
Malkiewicz JJ; Siuda J
Neurol Neurochir Pol; 2024; 58(2):193-202. PubMed ID: 38148738
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.
Fiorenzato E; Antonini A; Camparini V; Weis L; Semenza C; Biundo R
J Neural Transm (Vienna); 2019 Nov; 126(11):1437-1445. PubMed ID: 31432258
[TBL] [Abstract][Full Text] [Related]
7. Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.
Aerqin Q; Jia SS; Shen XN; Li Q; Chen KL; Ou YN; Huang YY; Dong Q; Chen SF; Yu JT
J Alzheimers Dis; 2022; 90(2):761-773. PubMed ID: 36189590
[TBL] [Abstract][Full Text] [Related]
8. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.
De Pablo-Fernández E; Courtney R; Warner TT; Holton JL
JAMA Neurol; 2018 Aug; 75(8):1008-1012. PubMed ID: 29710120
[TBL] [Abstract][Full Text] [Related]
9. Serum adiponectin levels between patients with Parkinson's disease and those with PSP.
Kataoka H; Sugie K
Neurol Sci; 2020 May; 41(5):1125-1131. PubMed ID: 31897945
[TBL] [Abstract][Full Text] [Related]
10. Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy.
Kim KJ; Jeong SJ; Kim JM
Neurourol Urodyn; 2018 Jun; 37(5):1724-1730. PubMed ID: 29356135
[TBL] [Abstract][Full Text] [Related]
11. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Santangelo G; Cuoco S; Pellecchia MT; Erro R; Barone P; Picillo M
J Neurol; 2018 Nov; 265(11):2602-2613. PubMed ID: 30178175
[TBL] [Abstract][Full Text] [Related]
12. Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease.
Kass-Iliyya L; Kobylecki C; McDonald KR; Gerhard A; Silverdale MA
Brain Behav; 2015 May; 5(5):e00320. PubMed ID: 25874161
[TBL] [Abstract][Full Text] [Related]
13. Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease.
Ueno SI; Hatano T; Okuzumi A; Saiki S; Oji Y; Mori A; Koinuma T; Fujimaki M; Takeshige-Amano H; Kondo A; Yoshikawa N; Nojiri T; Kurano M; Yasukawa K; Yatomi Y; Ikeda H; Hattori N
Ann Clin Transl Neurol; 2020 Mar; 7(3):307-317. PubMed ID: 32059082
[TBL] [Abstract][Full Text] [Related]
14. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Ashour R; Jankovic J
Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460
[TBL] [Abstract][Full Text] [Related]
15. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
Rusz J; Bonnet C; Klempíř J; Tykalová T; Baborová E; Novotný M; Rulseh A; Růžička E
J Neurol; 2015; 262(4):992-1001. PubMed ID: 25683763
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson's disease.
Krishnan S; Mathuranath PS; Sarma S; Kishore A
Neurol India; 2006 Sep; 54(3):268-72. PubMed ID: 16936386
[TBL] [Abstract][Full Text] [Related]
17. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
[TBL] [Abstract][Full Text] [Related]
18. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations.
Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
Mov Disord; 2006 Jul; 21(7):989-96. PubMed ID: 16602104
[TBL] [Abstract][Full Text] [Related]
19. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
[TBL] [Abstract][Full Text] [Related]
20. Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders.
Yamamoto T; Tateno F; Sakakibara R; Furukawa S; Asahina M; Uchiyama T; Hirano S; Yamanaka Y; Fuse M; Koga Y; Yanagisawa M; Kuwabara S
PLoS One; 2016; 11(2):e0149278. PubMed ID: 26886104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
